CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

Similar documents
BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

KNR Constructions Robust Performance on Execution Ramp-up

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

Near-term pressure, but long-term outlook positive

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

Sonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.

Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

Central Depository Services

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

Healty cigarette-driven growth

Central Depository Services

Central Depository Services

BLS International Services

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Crompton Greaves Consumer Electricals

Amber Enterprises India Ltd

Crompton Greaves Consumer Electricals

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Multi Commodity Exchange

Simplex Infrastructures

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Adani Ports & SEZ Rating: Target price: EPS:

HCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.

Colgate-Palmolive (India)

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

Gillette India. Institutional Equities. 1QFY18 Result Update

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Visaka Industries Ltd

Ahluwalia Contracts (India)

TTK Prestige Ltd. Result Highlights. Revenue growth of 41% YoY, shows no slowdown yet. OPM at ~15.8%; in line with our estimate

Hindustan Media Ventures

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

Institutional Equities

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

Fineotex Chemical Ltd

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Parag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months

Transport Corporation of India Ltd.

Transport Corporation of India Ltd.

Mahindra & Mahindra Ltd.

Mahindra & Mahindra Ltd.

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

Religare Investment Call

Intellect Design Arena

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Initiating Coverage. Uflex Ltd.

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

Wipro. 3QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 328. Recommendation: Hold

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Cummins India Ltd Bloomberg Code: KKC IN

Parag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months

SQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E

Bajaj Finance Limited (BFL) NBFC. BUY Rating as per Large Cap 12 months investment period RETAIL EQUITY RESEARCH

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

NIIT Technologies. 3QFY19 Result Update. Robust revenue visibility, Outlook robust

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Transcription:

3QFY18 Result Update January 23, 2018 CMP* (Rs) 360 IN Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5 Stellar Performance; Fundamentals Remain Intact Central Depository Services () has reported another impressive financial performance in 3QFY18. Surpassing our estimates by 9%, its revenue rose by a healthy 36.1% YoY to Rs511mn, led by robust growth in key verticals, including Transaction Charges (+67% YoY), IPO/Corporate Action Charges (+122%) and KYC/Online Data Charges (+74%). From a segmental perspective, while revenue from Depository Services rose by 31.1% YoY to Rs395mn, revenue from Data Processing surged by a robust 58.1% YoY to Rs109mn. This impressive performance on revenue front can be attributed to good health of capital markets, with the key indices hitting all-time highs, robust primary market with new issuers coming in at a rapid rate and strong number of new demat account openings. Notably, its EBITDA margin expanded by a whopping 785bps YoY to 61.1%, which in absolute terms grew by 56.2% YoY to Rs312mn owing to operating leverage and eective cost control measures. However, its reported PAT rose at a slower pace than EBITDA albeit still at a healthy pace by 25.3% YoY to Rs254mn owing to 38.4% YoY decline in lower other income led by higher yields on investments, which led to falling bond prices. Share price (%) 1 mth 3 mth 12 mth Absolute performance (2.1) (4.1) N.A. Relative to Nifty (7.3) (12.7) N.A. Shareholding Pattern (%) Sep'17 Dec'17 Promoter 24.0 24.0 Public 76.0 76.0 1 Year Stock Price Performance 450 430 410 390 370 350 Revenue Growth, Margins Impress 330 310 Aided by all-round growth in both Depository and Data Processing segments, s revenue 290 grew by an impressive 36.1% YoY to Rs511mn. Its revenue from Depository Services rose by 270 250 31.1% YoY (9.6% QoQ) to Rs395mn, aided by healthy capital markets, strong primary market Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 and growth in DP accounts due to increasing investor interest. Further, its revenue from Data Processing surged by a robust 58.1% YoY (7.7% QoQ) to Rs109mn aided by healthy state of capital Note: * CMP as on January 22, 2018 markets and strong downstream revenue relating to KYC services led by new demat account openings. EBIT margin from Depository segment expanded by a strong 769bps YoY, while segmental EBIT surged by 53.9% YoY to Rs205mn. On the other hand, EBIT margin from Data Processing segment rose by 313bps YoY, while segmental EBIT rose by 64.6% YoY to Rs87mn. Thus, its consolidated EBIT margin rose by 673bps YoY to 57.5%, while consolidated EBIT surged by 54.2% YoY. Outlook & Valuation We continue to believe s stock is a good long-term investment in light of its highly predictable revenue model, good health of capital markets, market leadership based on incremental BO accounts, sustainable cash flow and newer business initiatives. At CMP, the stock trades at a PE of 29.3x/25.5x FY19E/FY20E EPS, respectively. Rolling over our estimates to FY20E, we maintain our recommendation on the stock with a revised Target Price of Rs450 (from Rs435 earlier). Key Financials (Rs mn) FY17 FY18E FY19E FY20E Net Sales 1,460 1,949 2,441 2,832 EBITDA 794 1,169 1,483 1,742 RPAT 858 1,049 1,283 1,476 Diluted EPS (Rs) 8.2 10.0 12.3 14.1 P/E (x) 43.9 35.9 29.3 25.5 Research Analyst: Harit Shah EV / EBITDA (x) 43.9 29.2 22.5 18.6 Contact: 022 33201276 RoE (%) 16.9 18.5 20.0 20.2 Email: harit.shah@relianceada.com 1

IN Conference Call Key Takeaways continues to remain the leader in demat segment in terms of incremental market share, at 64%. The company had Rs5.3bn cash on its books as of 3QFY18-end. Other income declined by 38.4% YoY owing to higher yields on investments, which led to falling bond prices. earned 7.52% yield on its bond investments during 9MFY18 compared to 9.78% in the year-ago period. One of its new initiatives i.e. National Academic Depository (NAD) is witnessing good traction with new universities and academic institutions having signed ups. Though cannot charge the universities for 2 years, it can collect verification charges from academic institutions and testing agencies. However, as these institutions are typically slow in uploading data, it could take some time before is able to monetise this segment. Risks to the View Emergence of new technologies like Blockchain could aect s e-voting and KYC biz. Fierce price competition from key competitor i.e. NSDL. Any sustained downturn in equity markets. Appointment of CERSAI as central KYC registration agency could impact Ventures KYC business, which contributed 12.8% to s total revenue in FY17. Generic risks typically faced by electronic online systems such as cyber-attacks. Exhibit 1: Quarterly Performance (Consolidated) Particulars (Rs mn) 3QFY18 3QFY17 YoY (%) 2QFY18 QoQ (%) Net Revenues 511 376 36.1 472 8.2 Employee Expenses 71 61 15.8 66 7.5 Other Operating Expenses 128 114 11.9 106 20.0 EBITDA 312 200 56.2 300 4.2 Depreciation 18 9 97.3 14 31.8 EBIT 294 191 54.2 286 2.8 Other Income 59 96 (38.4) 91 (34.7) PBT 353 287 23.2 377 (6.2) Minority Interest and associate profits 0 1 (71.1) 1 (69.2) Tax 99 83 19.4 108 (8.3) APAT 254 202 25.3 267 (5.1) E/o (adj for tax) 0 0-0 - RPAT 254 202 25.3 267 (5.1) 2

IN Exhibit 2: Margin Break Up Particulars (%) 3QFY18 3QFY17 YoY (bps) 2QFY18 QoQ (bps) Employee Expenses % Net Revenues 13.9 16.4 (244) 14.0 (9) Other Expenses % Net Revenues 25.0 30.4 (540) 22.5 245 EBITDA Margin (%) 61.1 53.3 785 63.5 (236) EBIT Margin (%) 57.5 50.8 673 60.5 (301) Tax Rate (%) 28.1 29.0 (87) 28.7 (64) APAT Margin (%) 49.6 53.9 (428) 56.6 (694) Exhibit 3: Earlier, revised estimates Particulars Earlier estimates Revised estimates % change Earlier estimates Revised estimates % change FY19E FY20E Revenue (Rs mn) 2,149 2,441 13.6 2,427 2,832 16.7 EBITDA (Rs mn) 1,274 1,483 16.4 1,456 1,742 19.6 EBITDA margin (%) 59.3 60.8 150 bps 60.0 61.5 150 bps EPS (Rs) 11.7 12.3 5.0 13.2 14.1 7.0 Source: RSec Research Exhibit 4: Segment-wise contribution (% of gross revenue) 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 3QFY18 Depository Activity 76.1 78.5 79.8 76.9 73.0 75.9 76.7 Data Processing Services 21.7 19.4 18.3 21.7 23.9 21.4 21.3 Others 2.1 2.1 1.8 1.4 3.1 2.7 2.0 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Exhibit 5: Segment-wise growth (YoY, %) 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 3QFY18 Depository Activity 42.0 42.0 (1.7) 19.0 23.1 18.2 31.1 Data Processing Services 9.8 10.2 21.4 12.1 41.4 35.2 58.1 Others 11.5 3.5 14.1 (26.5) 87.1 56.0 47.8 Total 33.0 32.8 1.6 15.8 28.6 22.4 36.1 Exhibit 6: Segment-wise EBIT margins (% of revenue) 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 3QFY18 Depository Activity 41.2 52.6 44.3 39.4 43.5 56.2 52.0 Data Processing Services 79.7 81.9 76.7 78.2 82.6 76.2 79.8 Others 63.0 69.3 61.4 (29.9) 72.1 47.8 14.0 Total 50.3 58.9 50.8 47.1 54.0 60.5 57.5 Exhibit 7: Segment-wise EBIT contribution (% of gross EBIT) 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 3QFY18 Depository Activity 62.7 70.5 69.9 64.7 59.1 70.8 69.8 Data Processing Services 34.6 27.1 27.8 36.2 36.7 27.1 29.7 Others 2.7 2.5 2.2 (0.9) 4.2 2.1 0.5 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 3

IN Profit and Loss Statement Y/E March (Rs mn) FY17 FY18E FY19E FY20E Net Sales 1,460 1,949 2,441 2,832 Growth (%) 18.8 33.5 25.2 16.0 Employee Expenses 249 292 360 411 Other Expenses 417 487 598 680 EBITDA 794 1,169 1,483 1,742 EBITDA (%) 54.4 60.0 60.8 61.5 EBITDA Growth (%) 24.3 47.2 26.8 17.5 Depreciation & Amortisation 37 64 66 69 EBIT 757 1,106 1,417 1,673 EBIT (%) 51.9 56.7 58.0 59.1 EBIT Growth (%) 26.8 46.1 28.1 18.1 Other Income 408 342 365 389 PBT Margin (%) 79.8 74.3 73.0 72.8 PBT Growth (%) 18.7 24.3 23.0 15.7 Tax (incl deferred) 300 391 490 577 Minority Interest 8 8 8 8 Extraordinary Items 0 0 0 0 APAT 858 1,049 1,283 1,476 PAT Margin (%) 58.8 53.8 52.6 52.1 PAT Growth (%) (5.7) 22.3 22.3 15.0 EPS (Rs) 8.2 10.0 12.3 14.1 EPS Growth (%) (5.7) 22.3 22.3 15.0 Balance Sheet Y/E March (Rs mn) FY17 FY18E FY19E FY20E SOURCES OF FUNDS Share Capital - Equity 1,045 1,045 1,045 1,045 Reserves 4,288 4,960 5,781 6,726 Total Shareholders' Funds 5,333 6,005 6,826 7,771 Minority Interest 155 163 171 179 Long Term Provisions & Others 6 6 6 6 Deferred Tax Liabilities (Net) 7 7 7 7 Creditors 90 96 118 134 Other Current Liabilities & Provns 481 494 514 529 Total Current Liabilities 571 590 632 663 TOTAL SOURCES OF FUNDS 6,072 6,771 7,643 8,627 APPLICATION OF FUNDS Net Block 47 41 37 24 Goodwill & Other Intangible Assets 8 8 8 8 Investments 2,729 2,729 2,729 2,729 Deferred Tax Assets 23 23 23 23 LT Loans & Advances, Others 228 228 228 228 Total Non Current Assets 3,035 3,030 3,025 3,012 Cash & Bank 483 1,133 1,942 2,883 Liquid Investments 2,300 2,300 2,300 2,300 Debtors 133 187 254 310 Loans & Advances and Others 122 122 122 122 Total Current Assets 3,038 3,742 4,618 5,615 TOTAL APPLICATION OF FUNDS 6,072 6,771 7,643 8,627 4

IN Cash Flow Statement Y/E March (Rs mn) FY17 FY18E FY19E FY20E PAT 858 1,094 1,272 1,419 Non-operating & EO items 0 (63) (77) (89) Depreciation 37 64 66 69 Working Capital Change (101) (35) (25) (24) Cash Flow from Operations (a) 794 1,059 1,236 1,375 Capex (53) (58) (61) (57) Investments 235 0 0 0 Cash Flow from Investing (b) 182 (58) (61) (57) Debt Issuance/(Repaid) 0 0 0 0 Share capital Issuance 0 0 0 0 Dividend (314) (315) (385) (443) Cash Flow from Financing (c) (314) (315) (385) (443) NET CASH FLOW (a+b+c) 662 686 790 875 EO items, others (609) (37) 20 65 Closing Cash Balance 483 1,133 1,942 2,883 Free Cash Flow 742 1,001 1,175 1,318 Key Ratios Y/E March FY17 FY18E FY19E FY20E Profitability (%) EBITDA Margin 54.4 60.0 60.8 57.0 APAT Margin 58.8 53.8 52.6 57.4 RoE 16.9 18.5 20.0 20.2 RoIC or Core RoCE 101.2 138.0 160.4 173.8 RoCE 11.1 14.2 16.0 16.5 Eiciency Tax Rate (%) 25.7 27.0 27.5 28.0 Fixed Asset Turnover (x) 14.5 12.3 11.1 10.2 Payables (days) 49 45 45 45 Cash Conversion Cycle (days) (16) (10) (7) (5) Net Debt/EBITDA (x) (6.9) (5.3) (4.7) (4.5) Net Debt/Equity (x) (1.0) (1.0) (1.0) (1.0) Interest Coverage (x) N.A. N.A. N.A. N.A. Per Share Data (Rs) EPS 8.2 10.0 12.3 13.6 CEPS 8.6 10.6 12.9 14.8 DPS 2.5 3.0 3.7 4.2 BV 51.0 57.5 65.3 74.4 Valuation P/E (x) 43.9 35.9 29.3 25.5 P/BV (x) 7.1 6.3 5.5 4.8 EV/EBITDA (x) 43.9 29.2 22.5 18.6 OCF/EV (%) 2.3 3.1 3.7 4.3 FCF/EV (%) 2.1 2.9 3.5 8.9 FCFE/mkt cap (%) 2.0 2.7 3.1 7.7 Dividend Yield (%) 0.7 0.8 1.0 1.2 5

IN Rating Guides Rating Expected absolute returns (%) over 12 months >10% HOLD -5% to 10% REDUCE >-5% Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or oering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, ailiates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, ailiates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely aected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces aecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be aected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may aect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/ opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an oicer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. ( Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 6